These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 25485923

  • 1. Strategies for urgent reversal of target-specific oral anticoagulants.
    Davis EM, Uhlmeyer EM, Schmidt DP, Schardt GL.
    Hosp Pract (1995); 2014 Dec; 42(5):108-25. PubMed ID: 25485923
    [Abstract] [Full Text] [Related]

  • 2. Bleeding and antidotes in new oral anticoagulants.
    Majeed A, Schulman S.
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [Abstract] [Full Text] [Related]

  • 3. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [Abstract] [Full Text] [Related]

  • 4. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS.
    Am J Health Syst Pharm; 2013 May 15; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [Abstract] [Full Text] [Related]

  • 5. How I treat target-specific oral anticoagulant-associated bleeding.
    Siegal DM, Garcia DA, Crowther MA.
    Blood; 2014 Feb 20; 123(8):1152-8. PubMed ID: 24385535
    [Abstract] [Full Text] [Related]

  • 6. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep 20; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 7. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
    J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324
    [Abstract] [Full Text] [Related]

  • 8. Direct oral anticoagulants in atrial fibrillation.
    Noll G, Noll S, Hürlimann D.
    Semin Hematol; 2014 Apr 21; 51(2):139-46. PubMed ID: 24861798
    [Abstract] [Full Text] [Related]

  • 9. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, Lip GY.
    Int J Cardiol; 2015 Jan 20; 179():279-87. PubMed ID: 25464465
    [Abstract] [Full Text] [Related]

  • 10. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R.
    Clin Res Cardiol; 2013 Jun 20; 102(6):399-412. PubMed ID: 23669868
    [Abstract] [Full Text] [Related]

  • 11. Management of hemorrhage with the target-specific oral anticoagulants.
    Pluym M, Howell G.
    Hosp Pract (1995); 2014 Aug 20; 42(3):75-83. PubMed ID: 25255409
    [Abstract] [Full Text] [Related]

  • 12. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A, Daw HA, Crowther MA.
    Cleve Clin J Med; 2013 Jul 20; 80(7):443-51. PubMed ID: 23821689
    [Abstract] [Full Text] [Related]

  • 13. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr 20; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 14. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M, Obońska K, Kubica A, Navarese EP, Kubica J.
    Kardiol Pol; 2012 Apr 20; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 20; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 16. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P, Working Group on Perioperative Haemostasis.
    Arch Cardiovasc Dis; 2013 Aug 20; 106(6-7):382-93. PubMed ID: 23810130
    [Abstract] [Full Text] [Related]

  • 17. Managing new oral anticoagulants in the perioperative and intensive care unit setting.
    Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM.
    Anesthesiology; 2013 Jun 20; 118(6):1466-74. PubMed ID: 23416382
    [Abstract] [Full Text] [Related]

  • 18. The novel anticoagulants: the surgeons' prospective.
    Shamoun FE, Martin EN, Money SR.
    Surgery; 2013 Mar 20; 153(3):303-7. PubMed ID: 23218887
    [Abstract] [Full Text] [Related]

  • 19. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
    Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ.
    Biomed Res Int; 2014 Mar 20; 2014():583794. PubMed ID: 25136597
    [Abstract] [Full Text] [Related]

  • 20. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S.
    Thromb Haemost; 2014 Apr 01; 111(4):575-82. PubMed ID: 24452881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.